MDxHealth Suspends 2026 Guidance After Q3 Revenue Misses, Sales Force Exodus
MDXH sits 51% above its 52-week low of $0.4 on light trading volume (0.1× avg).
Summary
MDxHealth pre-announced Q3 revenue of roughly $22.7M, flat versus the prior year and well short of the $110-115M full-year pace it had guided to, and pulled that guidance entirely. Tissue-based test volume (Confirm mdx, GPS mdx) fell 11% year-over-year to 11,232, which the CEO blamed on unexpected sales force turnover driven by aggressive recruiting after the Resolve mdx discontinuation. Liquid-based Exo mdx volume grew to 11,792 from 4,600, but that comparison includes the September 2025 acquisition and does not offset the core tissue decline. Cash stood at about $31.7M as of September 30, a thin cushion for a company that just lost its revenue trajectory and is still dealing with a $10.4M Medicare recoupment claim and Nasdaq minimum market value deficiency disclosed in July. The stock trades near $0.60 with a market cap under $60M, so the guidance withdrawal removes the primary anchor for valuation and raises the odds of another capital raise. Full Q3 results and corrective-action detail are due on the November 12 earnings call.
At the time of this announcement, MDXH was trading at $0.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $57.6M. The 52-week trading range was $0.40 to $5.33. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.